Overview

Description

  • NatureSynthetic

Associated products

Specifications

Our Abpromise guarantee covers the use of ab86940 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

  • Applications

    Blocking - Blocking peptide for Anti-FGF9 antibody (ab71395)

  • Purity70 - 90% by HPLC.

  • FormLiquid
  • Additional notes

    - First try to dissolve a small amount of peptide in either water or buffer. The more charged residues on a peptide, the more soluble it is in aqueous solutions.
    - If the peptide doesn’t dissolve try an organic solvent e.g. DMSO, then dilute using water or buffer.
    - Consider that any solvent used must be compatible with your assay. If a peptide does not dissolve and you need to recover it, lyophilise to remove the solvent.
    - Gentle warming and sonication can effectively aid peptide solubilisation. If the solution is cloudy or has gelled the peptide may be in suspension rather than solubilised.
    - Peptides containing cysteine are easily oxidised, so should be prepared in solution just prior to use.

  • Concentration information loading...

Preparation and Storage

  • Stability and Storage

    Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.

    Information available upon request.

General Info

  • Alternative names
    • FGF 9
    • FGF-9
    • FGF9
    • FGF9_HUMAN
    • Fibroblast growth factor 9
    • GAF
    • Glia Activating Factor
    • Glia-activating factor
    • HBFG 9
    • HBFG9
    • HBGF-9
    • Heparin-binding growth factor 9
    • MGC119914
    • MGC119915
    • SYNS3
    see all
  • FunctionMay have a role in glial cell growth and differentiation during development, gliosis during repair and regeneration of brain tissue after damage, differentiation and survival of neuronal cells, and growth stimulation of glial tumors.
  • Tissue specificityGlial cells.
  • Involvement in diseaseDefects in FGF9 are the cause of multiple synostoses syndrome type 3 (SYNS3) [MIM:612961]. Multiple synostoses syndrome is an autosomal dominant condition characterized by progressive joint fusions of the fingers, wrists, ankles and cervical spine, characteristic facies and progressive conductive deafness.
  • Sequence similaritiesBelongs to the heparin-binding growth factors family.
  • Post-translational
    modifications
    Three molecular species were found (30 kDa, 29 kDa and 25 kDa), cleaved at Leu-4, Val-13 and Ser-34 respectively. The smaller ones might be products of proteolytic digestion. Furthermore, there may be a functional signal sequence in the 30 kDa species which is uncleavable in the secretion step.
    N-glycosylated.
  • Cellular localizationSecreted.
  • Information by UniProt

References for Human FGF9 peptide (ab86940)

ab86940 has not yet been referenced specifically in any publications.

Product Wall

Vielen Dank für Ihre Anfrage.

Leider haben wir nicht das passende Blockpeptid für den ab106245 Anti-FGF2 antibody in unserem Katalog, dafür aber das aktive, rekommbinate Protein ab129033:

Click here (or use the following: http://w...

Read More

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"